

9HPT (Non-dominant hand): Change from Part 1 baseline to each scheduled efficacy visit in Part 2
 Subgroup Analysis: Confirmed Progression of disability
 ITT population

Confirmed Progressors

| | Placebo to Natalizumab 300 mg | Natalizumab 300 mg | p-value (a) |
|----------------------------------|----------------------------------|-----------------------|-------------|
| Change from Baseline to Week 156 | | | |
| n | 155 | 137 | |
| Mean | 11.25 | 11.25 | 0.8781 |
| SD | 39.513 | 38.296 | |

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (≤ 5.5 or ≥ 6) and baseline 9HPT (non-dominant hand).

9HPT (Non-dominant hand): Change from Part 1 baseline to each scheduled efficacy visit in Part 2
 Subgroup Analysis: Confirmed Progression of disability
 ITT population

Non Progressors

| | Placebo to Natalizumab 300 mg | Natalizumab 300 mg | p-value (a) |
|----------------------------------|----------------------------------|-----------------------|-------------|
| Change from Baseline to Week 156 | | | |
| n | 99 | 132 | |
| Mean | -4.17 | -2.26 | 0.2751 |
| SD | 13.999 | 16.311 | |

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (<=5.5 or >=6) and baseline 9HPT (non-dominant hand).